Literature DB >> 21109234

Effects of modafinil on emotional processing in first episode psychosis.

Linda Scoriels1, Jennifer H Barnett, Graham K Murray, Srinivasarao Cherukuru, Mark Fielding, Frances Cheng, Belinda R Lennox, Barbara J Sahakian, Peter B Jones.   

Abstract

BACKGROUND: Emotional impairments are important determinants of functional outcome in psychosis, and current treatments are not particularly effective. Modafinil is a wake-promoting drug that has been shown to improve emotion discrimination in healthy individuals and attention and executive function in schizophrenia. We aimed to establish whether modafinil might have a role in the adjuvant treatment of emotional impairments in the first episode of psychosis, when therapeutic endeavor is arguably most vital.
METHODS: Forty patients with a first episode of psychosis participated in a randomized, double-blind, placebo-controlled crossover design study testing the effects of a single dose of 200 mg modafinil on neuropsychological performance. Emotional functions were evaluated with the emotional face recognition test, the affective go-no go task, and the reward and punishment learning test. Visual analogue scales were used throughout the study to assess subjective mood changes.
RESULTS: Modafinil significantly improved the recognition of sad facial expressions (z = 2.98, p = .003). In contrast, there was no effect of modafinil on subjective mood ratings, on tasks measuring emotional sensitivity to reward or punishment, or on interference of emotional valence on cognitive function, as measured by the affective go-no go task.
CONCLUSIONS: Modafinil improves the analysis of emotional face expressions. This might enhance social function in people with a first episode of psychosis.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109234     DOI: 10.1016/j.biopsych.2010.09.043

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens.

Authors:  Takuya Funayama; Yumiko Ikeda; Amane Tateno; Hidehiko Takahashi; Yoshiro Okubo; Haruhisa Fukayama; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.

Authors:  Laura Christina Wittkampf; Johannes Arends; Leo Timmerman; Marike Lancel
Journal:  Ther Adv Psychopharmacol       Date:  2012-06

Review 3.  Modafinil for people with schizophrenia or related disorders.

Authors:  Javier Ortiz-Orendain; Sergio A Covarrubias-Castillo; Alan Omar Vazquez-Alvarez; Santiago Castiello-de Obeso; Gustavo E Arias Quiñones; Maya Seegers; Luis Enrique Colunga-Lozano
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

Review 4.  Cognitive mechanisms of treatment in depression.

Authors:  Jonathan P Roiser; Rebecca Elliott; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2011-10-05       Impact factor: 7.853

5.  Emotion recognition and oxytocin in patients with schizophrenia.

Authors:  B B Averbeck; T Bobin; S Evans; S S Shergill
Journal:  Psychol Med       Date:  2011-08-11       Impact factor: 7.723

Review 6.  The ethics of elective psychopharmacology.

Authors:  Ahmed D Mohamed; Barbara J Sahakian
Journal:  Int J Neuropsychopharmacol       Date:  2011-03-14       Impact factor: 5.176

7.  Behavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.

Authors:  L Scoriels; R M Salek; E Goodby; D Grainger; A M Dean; J A West; J L Griffin; J Suckling; P J Nathan; B R Lennox; G K Murray; E T Bullmore; P B Jones
Journal:  Transl Psychiatry       Date:  2015-03-31       Impact factor: 6.222

8.  Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.

Authors:  Patrick C Dolder; Felix Müller; Yasmin Schmid; Stefan J Borgwardt; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2017-05-27       Impact factor: 4.530

9.  Cognitive profiling and proteomic analysis of the modafinil analogue S-CE-123 in experienced aged rats.

Authors:  István Gyertyán; Jana Lubec; Alíz Judit Ernyey; Christopher Gerner; Ferenc Kassai; Predrag Kalaba; Kata Kozma; Iva Cobankovic; Gábor Brenner; Judith Wackerlig; Eva Franschitz; Ernst Urban; Thierry Langer; Jovana Malikovic; Gert Lubec
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

Review 10.  The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.

Authors:  Barbara J Sahakian; Annette B Bruhl; Jennifer Cook; Clare Killikelly; George Savulich; Thomas Piercy; Sepehr Hafizi; Jesus Perez; Emilio Fernandez-Egea; John Suckling; Peter B Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.